Komal Jhaveri MD, FACP

Dr. Komal Jhaveri, MD, FACP, Attending Physician at Memorial Sloan Kettering Cancer Center, Clinical Director of the Early Drug Development Service, and Assistant Professor of Medicine at Weill Cornell Medical College, served as the study’s invited discussant.

Dr. Jhaveri noted that, in SOLAR-1, the treatment benefit with alpelisib was observed regardless of prior CDK4/6 inhibition, although the population of CDK4/6-exposed patients accounted for just 6% of those enrolled. BYLieve showed the efficacy of alpelisib in a larger population and in patients who received a higher relative dose intensity. The higher dose intensity may have been the result of fewer hypoglycemia-related treatment discontinuations, she suggested, “which highlight the importance of incorporating effective management strategies.”